Generic combination HIV/AIDS drugs formulated into a single pill are "at least as [effective] as highly active antiretroviral therapy in industrialised countries", according to research published in this week's issue of The Lancet. Christian Laurent, of the French Institut de Recherche pour le Développement (IRD) and his colleagues took advantage of a pilot project on access to antiretroviral drugs in Yaoundé, the capital of Cameroon, to test the efficacy, safety and quality of one of the most commonly used fixed-dose combination (FDC) therapies used in Africa.